1. The prefusion F protein of RSV (RSVpreF) vaccine produces neutralizing antibodies against RSV in both the serum of the ...
1. EV71vac showed a vaccine efficacy of 96.8% against EV71-associated diseases. 2. Majority of adverse events were mild and self-limited ...
1. Seroconversion at 84 days was greater in the ZyCoV-D group compared to placebo. 2. The occurrence of adverse events ...
1. The AD26.COV2.S vaccine provided protection against moderate to severe-critical Covid-19. 2. The AD26.COV2.S vaccine provided protection against severe Covid-19 ...
1. In a retrospective cohort study, compared to the risk in the initial 90 days after receiving a 2nd dose, ...
1. In kidney transplant recipients (KTRs) who had no antibody response after a 2nd mRNA COVID-19 vaccine dose, there was ...
1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against ...
1. The majority of patients being treated for solid tumour cancers were adequate responders to the vaccine. 2. Serious adverse ...
1. In a cohort of Medicare beneficiaries, the recombinant zoster vaccine was associated with a slightly increased risk of Guillain-Barré ...
1. Out of 5,150,310 individuals in England that received two COVID-19 vaccine doses, 81 patients passed away from COVID-19 and 71 were ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.